by Ashley | May 4, 2021 | Clinical Trial, COVID-19, Press Release, Stem Cell
Just three months after the initial treatments, Personalized Stem Cells, Inc (PSC), a human adipose-derived stem cell company, announces enrollment is complete for COVID-19 FDA approved stem cell clinical trial licensed to Sorrento Therapeutics (Nasdaq: SRNE,...
by Ashley | Apr 30, 2021 | Blog, Clinical Trial, COVID-19
In February, we announced preliminary results in a COVID-19 stem cell clinical trial that we licensed to Sorrento Therapeutics. To give a bit of backstory for those who may be new to our blog, Personalized Stem Cells went to work in the early pandemic days to...
by Valet | Mar 19, 2021 | Blog, COVID-19, Regenerative Medicine, Stem Cell
While there are several sources of mesenchymal stem cells (MSCs), two of the most common sources include adipose tissue and bone marrow. At Personalized Stem Cells, we process adipose (fat) tissue to extract and concentrate MSCs for use in FDA-approved clinical...
by Valet | Feb 19, 2021 | Blog, Clinical Trial, COVID-19, FDA Approved Clinical Trial
In 2020, Personalized Stem Cells developed and secured FDA approval for a COVID-19 stem cell clinical trial. In October of last year, we announced that we out-licensed our allogeneic stem cell program, including the COVID-19 therapy, to Sorrento Therapeutics....
by Valet | Feb 4, 2021 | Clinical Trial, COVID-19, Press Release
Personalized Stem Cells, Inc (PSC), a human adipose-derived stem cell company, announces that the first patients have received stem cell therapy for the treatment of COVID-19 as part of an FDA approved clinical trial. The ongoing clinical trial and stem cell platform,...
by Ashley | Oct 16, 2020 | Blog, COVID-19, Personalized Stem Cells
Personalized Stem Cells is ‘Personalized’ for a reason. Our primary focus has always been on providing autologous adipose derived stem cell services to physicians for their patients. When the pandemic struck, however, we felt a call to action and our focus was...